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Abstract 
The Infectious Disease Ontology (IDO) is a suite of interoperable ontology modules that 
aims to provide coverage of all aspects of the infectious disease domain, including biomedical 
research, clinical care, and public health. IDO Core is designed to be a disease and pathogen neutral 
ontology, covering just those types of entities and relations that are relevant to infectious diseases 
generally. IDO Core is then extended by a collection of ontology modules focusing on specific 
diseases and pathogens. In this paper we present applications of IDO Core together with an 
overview of all IDO extension ontologies and the methodology on the basis of which they are built. 
We also survey recent developments involving IDO, including: IDO Virus (VIDO); the 
Coronaviruses Infectious Disease Ontology (CIDO); and an extension of CIDO focusing on 
COVID-19 (IDO-COVID-19). We discuss how these ontologies might assist in information-driven 
efforts to deal with the ongoing COVID-19 pandemic, to accelerate data discovery in the early 
stages of future pandemics, and to promote reproducibility of infectious disease research. 
 
1 INTRODUCTION 
 
1.1 Data Silos and the OBO Foundry 
 
Efforts by physicians, researchers, and public health organizations to respond to infectious diseases 
require the use of multiple, constantly changing data sources. Consider, for instance, a research team 
trying to build an effective, large-scale epidemiological system for modeling a given population’s 
herd immunity to measles. This depends on the integration of data not merely from biology and 
medicine, but also from statistics, sociology, and geography. The system will need to incorporate 
society-wide data on measles occurrence rates, transmission mode, birth rates, vaccination rates, 
family structures, age distribution, and other relevant demographic factors [1], and also patient-
specific data on clinical manifestations of disease, diagnoses, and treatments received. Because the 
relevant information is collected using discipline- and community-specific methodologies and is 
stored in heterogeneous and geographically distributed databases, the data are typically only locally 
accessible. The resultant silo-formation hinders both translational and comparative research and 
preventive and prognostic public health research.  
As the experience of biologists and bioinformaticians has shown, ontologies are an effective 
data sharing tool [2]. But in order for ontologies to be effective in this way, it is important that they 
are designed in a coordinated fashion – otherwise ontologies themselves will give rise to the creation 
of a new kind of silo. One of the most successful and widely adopted approaches to coordinated 
ontology development is that of the Open Biomedical Ontologies (OBO) Foundry1, a collective of 
 
1 http://obofoundry.org/ 
developer groups dedicated to creating, testing, and maintaining a collection of ontologies based on 
an evolving set of design principles for ontology development [3]. The principles include: 
 
• Ontologies should use a well-specified syntax and share a common space of identifiers.  
• Ontologies should be openly available in the public domain for reuse.  
• Ontologies in neighboring domains should be developed in a collaborative effort. 
• Ontologies should be developed in a modular fashion. 
• Ontologies should have a clearly specified scope.  
• Ontologies should use common unambiguously defined relations between their terms. 
• Ontologies should conform to a common top-level architecture.  
 
The OBO Foundry principles were modelled initially on the practices of the Gene Ontology (GO) 
[2], which is not only enormously successful in its own right but has also served as the model for a 
series of life science ontologies following in its wake.  
Wherever possible, Foundry ontologies are created utilizing terms and relational expressions 
taken from existing Foundry ontologies, including the Relation Ontology (RO) [4]. This practice is 
applied also to the terms and relational expressions used in the definitions in these ontologies, and it 
thereby helps to ensure cross-linkage between ontologies in neighboring domains and also to 
prevent redundant efforts. It also puts ontologies in a position where they can support integration of 
data across a wide range while avoiding the generation of silos. Ontologies aligning with OBO 
Foundry principles also require each class have a unique identifier with the bipartite form of ID-
space:Local-ID, as in GO:0008150. Use of such unique identifiers means that the source of each term 
– and specifically the version of the ontology from which it is drawn – can be immediately identified 
by its prefix. Use of unique identifiers also ensures that ontologies retain backward compatibility 
with legacy annotations as those ontologies evolve.  
Ontology construction and extension in accordance with these principles follows a ‘hub and 
spoke’ model, where a core or ‘hub’ ontology provides the basis for extension ontologies or ‘spokes’ 
which are created by a simple method of specialization. Following this model, the Infectious Disease 
Ontology (IDO) represents one step towards overcoming data silos [5], consisting of a central hub, 
formed by IDO Core, and series of spokes in which IDO Core is extended by terms specialized to 
specific pathogens. 
 
1.2 The Infectious Disease Ontology  
 
IDO Core is designed to be disease and pathogen neutral. It covers just those entities that 
are relevant to infectious diseases generally, covering aspects of infectious disease across biological 
scale (gene, cell, organ, organism, population), disciplinary perspective (clinical, biological, 
epidemiological), and the chain of infection (host, pathogen, vector, reservoir) [6]. IDO Core 
thereby provides a ‘hub’ for a collection of ontology ‘spokes’ focusing on specific diseases and 
pathogens. Taken together, these form the IDO suite of ontologies [5].  
Since IDO is built in accordance with the OBO Foundry principles described above, this 
puts IDO Core and its extensions in a position where they can promote interoperability with other 
ontologies built on the basis of the Foundry principles. This makes IDO Core and its extensions 
applicable to the annotation of a variety of databases relevant to infectious disease that already make 
use of Foundry ontologies in their annotations [5], as described in section 6 below.  
Relevant data and information within multiple disparate sources are annotated using the 
same set of IDO terms, which all use the same ID-space, namely “IDO”. Specific extension 
ontologies are demarcated via unique ID-blocks pre-assigned by the IDO Core team. The resultant 
annotated data thereby become available to computer processing as if it were a single body of linked 
data in virtue of the semantically controlled properties of these terms. These strategies have the 
benefits of preventing duplicate terms and efforts, enforcing the use of the same ontology 
development best practices, and encouraging tighter coordination between the IDO Core team and 
the teams responsible for each extension ontology [7], all of which are important for integration of 
data across the domain of infectious diseases.  
In the ideal case, all IDO extension ontologies would be developed in the same way, and in 
conformance to all Foundry principles. Unfortunately, not all of these principles have been followed 
faithfully in the IDO extension ontologies developed thus far. We believe, however, that the work 
described below on coronavirus-related extensions will serve as a model for the re-engineering of 
these extensions in such a way as to yield greater conformance. 
 
2 THE INFECTIOUS DISEASE ONTOLOGY 
 
2.1 IDO Term Requests 
While IDO Core was designed to provide coverage of the infectious disease domain 
generally, we never considered IDO Core to be complete and intended to have its expansion be 
driven by term requests. As with most OBO ontologies, IDO Core is an open project with its own 
GitHub repository2, where the most recent published and developmental versions of the ontology 
are available for download. We encourage members of the ontology community, as well as infectious 
disease researchers, to submit term requests to our GitHub Issues tracker. The Issues tracker can 
also be used to report any errors or concerns related to the ontology. Before requesting a new term, 
please search online ontology repositories such as Ontobee and BioPortal to see if the needed term 
already exists. Further advice is available in the OBO tutorial for term requests.3 Once a term 
request is received, it will be reviewed by the main IDO Core team to determine whether the term is 
most appropriate for IDO Core, one of its extensions, or another OBO ontology. If the term is 
within IDO Core’s scope, then it will be added with a formal definition, written in conjunction with 
the term requestor to ensure biological accuracy as well as adherence to OBO Foundry best 
practices and consistency with IDO logical structure. We can assign a unique ID for the term so that 
it can be used for immediate annotation prior to the definition being finalized. 
 
2.2 IDO Core Foundations  
At the heart of the IDO ontology ecosystem is the term ‘disease’, which is imported from 
the Ontology for General Medical Science (OGMS) [8]. The latter covers those types of entities 
relevant to clinical encounters between doctor and patient. Thus, it includes representations of 
disease, causes and manifestations of disease, diagnosis, symptom, treatment, patient examination, 
history taking, laboratory test, and so forth. While OGMS takes clinical encounters involving 
humans as its starting point, many of its terms can be applied to non-human organisms. OGMS is 
itself an extension of the Basic Formal Ontology (BFO), a top-level ontology comprised of highly 
general classes such as ‘object’, ‘material entity’, and ‘process’, and used by more than 300 ontology 
 
2 https://github.com/infectious-disease-ontology/infectious-disease-ontology  
3 https://github.com/jamesaoverton/obo-tutorial/blob/master/docs/ontology-development.md#filing-effective-term-
requests-and-bug-reports  
projects as their top-level architecture [9]. BFO is the official top-level ontology of the OBO 
Foundry, and it has recently been approved as international standard ISO/IEC 21838-2.4  
Developers of OGMS view the traditional practice of classifying diseases according to 
patterns of similarities in signs and symptoms (or, more generally, of phenotypes) as inadequate. A 
single disease may manifest a variety of symptoms making it difficult to distinguish from other 
diseases involving the same anatomical system. For example, Celiac disease shares many symptoms 
in common with Crohn’s disease, and another disease of the gut, that caused by Clostridioides difficile 
infection, which is often asymptomatic. Moreover, the traditional practice fails to address the 
increasing importance played by genetic and environmental variables in disease taxonomy. Seeking 
to address these issues, OGMS characterizes diseases in BFO terms as dispositions of patients to 
undergo pathological processes of specific kinds. Distinguishing manifestations of symptoms from 
dispositions to manifest symptoms provides the flexibility needed to represent, say, asymptomatic 
patients, for the latter are disposed to manifest symptoms. It also allows us to make sense of certain 
physician treatment recommendations, for example that patients on antibiotics should continue 
treatment after symptoms have subsided. In addition to distinguishing between disease, signs and 
symptoms, and pathological processes, OGMS further distinguishes between:  
 
• Diagnosis 
• A disease’s realization in a totality of processes forming what is called a disease course 
• Underlying disorders in which the disease is rooted. 
 
Where a disorder is characterized as a clinically abnormal feature of an organism, a feature that “(1) is 
not part of the life plan for an organism of the relevant type (unlike aging or pregnancy), (2) is 
causally linked to an elevated risk either of pain or other feelings of illness, or of death or 
dysfunction, and (3) is such that the elevated risk exceeds a certain threshold level” [8].  
These distinctions provide both the flexibility needed when characterizing disease-related 
phenomena and also the clarity and consistency needed for collection of accurate data where, for 
example, different clinicians diagnose the same disease differently, or where a disease exists without 
having been yet diagnosed [8]. The same disease may be manifested in a wide variety of different 
types of disease courses depending on the particular patient and on the treatment regimen. And 
since disorders can exist before they are realized in overt pathological processes, the OGMS 
approach allows for the existence of pre-clinical manifestations of disease, and for clinical risk factor 
combinations of disease and predispositions to disease (as when an instance of AIDS in a given 
patient is a risk factor for a second disease such as tuberculosis). Conflating these distinctions – 
which has been a problem in even widely-used medical vocabulary resources such as SNOMED-CT 
[10-12] – makes it more difficult to coherently count disease instances, which in turn may lead to 
incoherent reasoning about diseases, inconsistent models of specific diseases, errors in patient 
records, and failures to accurately measure progress in tackling disease spread.  
 
2.3 Extending IDO Core from OGMS 
 
IDO Core extends OGMS, and in doing so distinguishes between: 
• infectious disease  
• sign and/or symptom of infectious disease  
• infectious disease diagnosis  
 
4 https://www.iso.org/standard/74572.html, https://standards.iso.org/iso-iec/21838/-2/ed-1/en/  
• infectious disease course  
• infection  
 
The OGMS representation of the relationships between disease, disorder and disease courses is 
inherited by IDO Core as follows: 
 
 
Figure 1 
 
The relevant OGMS terms are defined as follows: 
Disorder =def. Material entity which is clinically abnormal and part of an extended organism; 
disorders are the physical basis of disease 
Disease =def. Disposition to (i) undergo pathological processes that (ii) exists in an organism 
because of one or more disorders in that organism 
Disease course =def. Process that is the totality of all processes through which a given disease 
instance is realized 
Extended organism =def. Object aggregate consisting of an organism and all material entities 
located within that organism overlapping the organism or occupying 
sites formed in part by the organism 
 
Has_material_basis  is a relational expression from BFO-ISO used to indicate the material basis of a 
disposition, in this case, a disease. The relevant IDO terms are defined as follows: 
Infection =def. Part of an extended organism that itself has an infectious agent population as 
part, exists as a result of processes initiated by members of the infectious agent 
population, and is: 
(1) Clinically abnormal in virtue of the presence of this infectious agent 
population or,  
(2) Has a disposition to bring clinical abnormality to immunocompetent 
organisms of the same Species as the host (the organism corresponding 
to the extended organism) through transmission of a member or 
offspring of a member of the infectious agent population. 
Infectious disorder =def. Infection that is clinically abnormal 
       Infectious disease =def. Disease whose physical basis is an infectious disorder 
Infectious disease course =def. Disease course that is a realization of an infectious disease 
 
To elucidate the definition of infection and make clearer its relationship to the classes disorder and 
infectious disorder, we first introduce further needed terms used by IDO Core. IDO Core imports the 
class organism from the Ontology for Biomedical Investigations (OBI) [13]. It also imports from the 
NCBI organismal classification (NCBITaxon)[14] classes for a variety of pathogenic organisms such 
as bacteria, as well as host organisms, such as homo sapiens, while a adding a new term virus (replacing 
the previously imported NCBIT:Viruses).  
IDO Core defines the following terms pertaining to hosts and pathogens:  
pathogenic disposition =def. Disposition to initiate processes that results in a disorder  
pathogen =def. Material entity with a pathogenic disposition 
pathogen role =def. Role borne by a pathogen in virtue of the fact that it or one of its products 
is sufficiently close to an organism towards which it has the pathogenic 
disposition to allow realization of the pathogenic disposition  
host role =def. Role borne by an organism in virtue of the fact that its extended organism 
contains a material entity other than the organism  
host =def. Organism bearing a host role 
establishment of localization in host =def. Establishment of localization process in which a 
material entity reaches a site in an organism in which it 
can survive, grow, multiply, or mature.  
 
IDO Core treats pathogens not as organisms, but as a child class of material entity, since some 
pathogens are not organisms. Anything that causes or can cause a disorder is a pathogen, including 
non-living things, such as prions. We chose not to define pathogenic disposition in terms of OGMS: 
etiological process, which is defined as a process in an organism that leads to a subsequent disorder [8], 
because this definition is incorrect. Etiology is about causes of anything, not just disorders. The 
most common use in medicine is to talk about the etiology of disease, but the term itself is broader. 
Building on its pathogen-related terms, IDO Core defines terms pertaining to infectious 
agents, their dispositions, and their roles (note the distinction between pathogen role and infectious agent 
role. Clostridium botulinum may bear the former but not the latter; various influenza virus strains, in 
contrast, may bear both): 
 
infectious disposition =def. Pathogenic disposition that inheres in an organism and is a 
disposition for that organism to:  
(1) be transmitted to a host,  
(2) establish itself in the host,  
(3) initiate processes that result in a disorder in the host, and  
   (4) become part of that disorder 
infectious agent =def. Organism that has an infectious disposition 
infectious agent population =def. Organism population whose members each have an    
infectious disposition. 
infectious agent role =def. Role borne by an infectious agent when contained in a host in which 
its infectious disposition can be realized. 
 
As well as defining various processes involved in the establishment of infections: 
colonization of host =def. Establishment of localization in host process in which an organism 
establishes itself in a host (Comment: Notice that where this class is 
restricted to organisms, its parent class includes any case of a pathogen 
establishing itself in a host, including prions.) 
process of establishing an infection =def. Process by which an infectious agent, established in a 
host, becomes part of an infection in the host 
establishment of a clinically abnormal colony =def. Colonization of host process that results in a 
clinically abnormal colony 
 
Clauses (1)-(4) of infectious disposition can be thought of as sub-dispositions all of which are borne by 
the infectious agent. Some organisms may have the disposition to be transmitted to but not to 
establish itself in the host, in which case they would not have the infectious disposition. According 
to IDO Core, if an infectious agent realizes its infectious disposition, (1)-(4) are realized sequentially. 
In some cases, an infectious agent may only be able to realize its infectious disposition partially, as 
when it is transmitted to a host, but fails to establish itself in the host due to the host’s immune 
response. When an infectious agent is transmitted to a host wherein all of its other subdispositions 
can be fully realized, it bears an infectious agent role. In this case, an infectious agent is able to colonize 
the host and then participate in a process of establishing an infection. If it participates in the establishment of 
a clinically abnormal colony and initiates processes that result in a disorder in the host, an infectious disorder 
is established. If an infection is established, but not a clinically abnormal colony, then the infection is 
not an infectious disorder. Within IDO Core, infectious disorder has the following logical definition: 
 
infectious disorder   infection AND disorder   
 
Note that the presence of commensal microorganisms within a host, as in the human microbiome, is 
not clinically abnormal as it is not causally linked to an elevated risk of either pain or other feelings 
of illness, or of death or dysfunction. By contrast, a dormant infectious agent population of a species 
that is not part of the host’s normal resident microbiota – as in the case of a latent infection – is 
clinically abnormal and for that reason an infectious disorder. Of course, commensals can also initiate 
disorders in their hosts, if they end up in the wrong anatomical site, as in the case of bacteremia 
(defined in IDO Core as “Infection that has as part bacteria located in the blood”), or if the 
populations grow out of control, as in the case of yeast infections.  
Some infections satisfy clause (2) of infection, but not clause (1), and so are not disorders. It is 
for this reason infection is not a subclass of disorder. An example would be an HIV infected human 
host that is resistant to the virus due to a mutation of the CCR5 gene. Such an infection is not 
clinically abnormal as it is not linked to an increased risk of dysfunction (and so on) in the resistant 
host. Instead, clause (2) is satisfied because the relevant infectious agent population is disposed to 
bring clinical abnormality to other potential immunocompetent human hosts without the mutation.  
 The IDO Core definition of infection thus allows for representation of commensal 
populations, infectious disorders that can be caused by organisms that are typically commensal, and 
the fact that asymptomatic infected individuals are contagious (as we see now with SARS-CoV-2).  
  
2.4 Transmission of Pathogens 
IDO Core recognizes the importance of characterizing infectious disease transmission in its various 
forms. IDO Core imports the following terms from the Pathogen Transmission Ontology5:  
transmission process =def. Process that is the means during which the pathogen is transmitted 
directly or indirectly from its natural reservoir, a susceptible host, or 
source to a new host 
indirect pathogen transmission process =def. Transmission process during which a pathogen is 
indirectly transferred from a reservoir, source or host 
to another host by intermediary vehicles, vectors, or 
as airborne dust particles 
 
A variety of infectious diseases, including malaria and dengue fever, are vector borne. Thus, IDO 
Core contains terms such as: 
infectious agent transporter role =def. Role borne by a material entity in virtue of the fact that an 
infectious agent is located in or on the entity and the entity has the 
capability to transfer (either actively or passively) the infectious 
agent from one location to another.   
infectious agent vector role =def. Infectious agent transporter role that is borne by an organism 
active in the transfer of an infectious agent to an organism of 
another Species and in which the agent is infectious 
infectious agent vector =def. Organism bearing an infectious agent vector role 
 
In other cases, infectious agents, such as the schistosoma parasites that cause schistosomiasis, spend part 
of their life cycle within intermediate hosts, after which the pathogen is transmitted into another 
medium, such as water, which then directly transmits the pathogen to susceptible organisms such as 
humans. Thus, IDO Core contains the following terms: 
symbiont host role =def. Host role borne by an organism in virtue of the fact that its extended 
organism contains a second organism and provides an environment 
supportive for the survival, growth, maturation, or reproduction of that 
organism 
intermediate host role =def. Symbiont host role borne by an organism in virtue of the fact that 
its partner in symbiosis utilizes the host to undergo development 
stage transition, and the host is required for continuation of the 
partner’s life cycle 
intermediate host =def. Organism bearing an intermediate host role 
 
Moreover, ‘symbiont host role’ includes further subclasses such as: 
 
definitive host role =def. Symbiont host role borne by an organism in virtue of the fact that its 
partner in symbiosis reaches developmental maturity or reproduces 
sexually in the host 
 
5 https://bioportal.bioontology.org/ontologies/PTRANS  
parasite host role =def. Symbiont host role borne by an organism in virtue of the fact that its 
partner in symbiosis derives from the host a growth, survival, or fitness 
advantage while the host's growth, survival, or fitness is reduced 
paratenic host role =def. Symbiont host role borne by an organism in virtue of the fact that its 
partner in symbiosis utilizes the host to undergo a developmental stage 
transition, but the host is not required for continuation of the partner's 
life cycle 
 
The preceding selection does not exhaust those host roles included in IDO Core but does reflect the 
wide range of ways in which to characterize host-symbiont relationships.  
 
2.5 Pathogen Inhibition and Control  
IDO Core provides several terms relevant to the inhibition and killing of pathogens: 
antibacterial disposition =def. Disposition to kill or inhibit the reproduction of bacteria  
antibacterial =def. Material entity bearing an antibacterial disposition 
antifungal disposition =def. Disposition to kill or inhibit the development or reproduction of 
fungal organisms  
antifungal =def. Material entity bearing an antifungal disposition 
antiparasitic disposition =def. Disposition to kill or inhibit the development or reproduction of 
eukaryotic parasites 
antiparasitic =def. Material entity bearing an antiparasitic disposition 
antiviral disposition =def. Disposition to kill or inhibit the lifecycle of viruses 
antiviral =def. Material entity bearing an antiviral disposition 
 
Relatedly, one of the most important applications of IDO is its treatment of the phenomenon of 
resistance. Examples of resistance include, a population’s herd immunity to certain populations of 
infectious organisms and the resistance of certain pathogens to antimicrobial drugs. The correct 
identification of different types of resistance is essential to both treatment decisions and public 
health policies [15]. For instance, varying strains of a given bacterial pathogen type (e.g. Staphylococcus 
aureus) can differ in terms of their degree of resistance and in the types of drug to which they are 
resistant. In the examples described above, resistance is a feature of an organism, or population of 
organisms, that serves to protect it/them from being damaged by some other entity. To capture this 
aspect of resistance, IDO Core contains the term protective resistance which is defined as follows: 
protective resistance =def. Disposition that inheres in a material entity in virtue of the fact that 
the entity has a part (e.g. a gene product), which itself has a disposition 
to mitigate damage to that entity 
Protective resistance includes not just drug resistance on the part of infectious agents or the 
resistance of hosts to infectious agents, but also things like the resistance of vectors to insecticide.  
Notice that what occurs in many cases where protective resistance is manifested is that 
another process is being prevented. Consider for instance the immunity of an individual X to a 
specific infectious organism Y that has the capability to cause damage to X. Given its infectious 
disposition, Y is disposed to be transmitted to and establish itself in X, initiate processes that result 
in a disorder in Y and become part of that disorder. X’s immunity to Y is realized in certain 
processes that prevent certain of the aforementioned processes from occurring, thus mitigating the 
damage those process potentially may have caused to X. To capture this aspect of resistance, 
protective resistance has been characterized in terms of what can be called “blocking dispositions” 
[6, 15], a disposition the manifestation of which prevents, or at least mitigates, the realization of 
another disposition. The disposition whose realization is prevented (or mitigated) can be called a 
“blocked disposition.” Thus, since X’s immunity to infectious organism Y is realized in processes 
that prevents certain realizations of Y’s infectious disposition, the former is a blocking disposition 
for the latter (the latter being a blocked disposition).  
This characterization of resistance is further enhanced in IDO Core by importing from RO the 
relation negatively_regulates, holding between processes x and y, and defined as: 
x negatively_regulates y =def. The progression of x reduces the frequency, rate or extent of y        
Thus, we can say that X’s immunity to Y is a blocking disposition for Y’s infectious disposition 
insofar that X’s immunity is realized in certain processes that negatively_regulate the manifestation of 
Y’s infectious disposition. For instance, X’s immunity may be realized in processes – such as, 
antibody secretion which would neutralize viral particles, preventing them from entering host cells – 
the progression of which reduces the rate at which, or the extent to which, Y establishes itself in X.  
2.6 Case Study: IDOSA and methicillin resistant Staphylococcus aureus 
IDO:protective resistance is used to model also the resistance of certain bacteria to antibiotic 
drugs. For this purpose, the following subtypes of protective resistance are asserted in IDO Core: 
drug resistance =def. Protective resistance that mitigates the damaging effects of a drug 
antibiotic resistance =def. Drug resistance that mitigates the damaging effects of an antibiotic  
Beta-lactam antibiotics such as methicillin are the most widely used antibiotics, and most work by 
preventing bacterial cell wall construction. Beta-lactam antibiotics act by binding to and inhibiting 
the penicillin-binding-proteins (PBPs) within bacteria that facilitate the synthesis of peptidoglycan 
molecules, thus compromising the structural integrity of the cell wall. In response to the widespread 
use of Beta-lactam antibiotics, some bacteria have rapidly evolved novel-structured PBPs which lack 
an affinity for these antibiotics, thus rendering them less effective. At a certain level, the description 
of antibacterial resistance seems to require a negative aspect; thus, the appeal to the fact that the 
PBPs of resistant bacteria lack an affinity for beta-lactam antibiotics. But negative characterizations 
of a phenomenon at one level of biological reality often belie its positive aspects at another level 
[15]. An important desideratum in the construction of realist ontologies is to avoid as far as possible 
the use of definitions involving negative differentia (such as ‘non-mammal’, ‘non-contagious’, ‘not 
part of an infection’). In compliance with this design principle of positivity, an ontologically correct 
representation of resistance will reveal the active mechanisms that produce resistance—in the case 
of resistant bacteria, the active dispositions inhering in novel-structured PBPs that inhibit antibiotics 
from manifesting their damaging effects [15].  
Consider the case of beta-lactam antibiotic resistance: methicillin resistant Staphylococcus aureus 
(MRSa). MRSa’s resistance to methicillin is conferred by PBP2a, a PBP that lacks affinity for 
methicillin and is the product of the gene mecA. The need to provide a coherent and consistent 
understanding of the mechanisms underlying MRSa antibiotic resistance is one impetus for the 
development of the Staphylococcus aureus Infectious Disease Ontology (IDOSA), an extension of IDO 
covering entities specific to Staph aureus (Sa) infectious diseases [6, 15, 16].  
IDOSA’s main hierarchy is built on BFO, and imports IDO Core in full. IDOSA provides 
terms covering all entities relevant to antibacterial resistance in Sa, including terms for proteins, 
genes, gene products, biological processes, and antibacterials. In addition, it imports  
• terms for Sa relevant proteins from the Protein Ontology (PRO) [17] 
• the terms gene, gene group, and mobile genetic element from the Sequence Ontology (SO) [18]  
• the term mecA – representing the gene responsible for the production of PBP2a in MRSa – 
from the Vaccine Ontology (VO) [19]  
• terms for biological processes such as peptidoglycan biosynthesis process and cytolysis in other organism 
(a subclass of killing of cells of other organisms) from the GO Biological Process Ontology 
• the term gram-positive bacterium-type cell wall from the GO Cellular Component Ontology 
• terms representing common anatomical sites of Sa infections, such as bone, lung, and 
endocardium, from the UBERON anatomy ontology [20] 
• terms for several beta-lactam antibiotics, including ciprofloxacin, methicillin, and penicillin from 
Chemical Entities of Biological Interest (ChEBI) [21] 
• the term staphylococcus aureus from NCBITaxon  
IDOSA also introduces several terms specific to the Sa domain, such as:  
• ccr gene complex and mec gene complex, added as subclasses of gene group  
• SCCMec, which is the central determinant for broad-spectrum beta-lactam resistance encoded 
by mecA, added as a subclass of mobile genetic element. 
The IDOSA subclasses methicillin-resistant Staphylococcus aureus and methicillin susceptible Staphylococcus 
aureus are defined as follows:  
methicillin-resistant Staphylococcus aureus =def. Organism of type Staphylococcus aureus that has 
resistance to beta-lactam antibiotics 
methicillin-susceptible Staphylococcus aureus =def. Organism of type Staphylococcus aureus that lacks 
resistance to beta-lactam antibiotics 
Both are defined in terms of IDOSA resistance to beta-lactam antibiotic, which itself is a subclass of 
IDO:antibiotic resistance and defined as follows: 
resistance to beta-lactam antibiotic =def. Antibiotic resistance that mitigates the damaging effects of a 
beta-lactam antibiotic  
With these terms and definitions, we can characterize both Methicillin-susceptible Staphylococcus aureus’s 
(MSSa) susceptibility, and MRSa’s resistance, to beta-lactam antibiotics in terms of protective resistance 
and blocking dispositions [6, 15].  
MSSa is susceptible to the damaging effects of methicillin because it lacks protective resistance to 
that drug. Characterized positively, MSSa’s PBPs have the disposition to undergo a methicillin PBP 
binding process that negatively_ regulates the synthesis of peptidoglycan, thereby interfering with the 
formation of a stable cell wall. Affinity for methicillin thus acts as a blocking disposition for the 
PBPs’ disposition to synthesize peptidoglycan.  
In the case of MRSa, in contrast, the disposition of its PBP2a parts to synthesize 
peptidoglycan, and thereby participate in the construction of a stable cell wall (which 
negatively_regulates methicillin binding), cannot be blocked. Thus, MRSa’s protective antibiotic resistance 
to methicillin can be seen as an active response in which PBP2a manifests a disposition to mitigate 
the damaging effects of methicillin. [15] shows how the formal representation of these relations can 
be used in association with instance data to draw inferences that may facilitate automated drug 
discovery and guide treatment decisions in specific types of cases.  
The IDO Core account of protective resistance can be applied also to other cases [15], such 
as the resistance against HIV conferred by CCR5-32, and the resistance against malaria conferred 
by the sickle cell trait. CCR5-32 is a deletion mutation of the CCR5 gene resulting in cells which 
lack a functioning CCR5 receptor on their surfaces. In this case, the disposition of individuals with 
the CCR5-32 mutation to develop cells that lack CCR5 on their surface acts as a blocking 
disposition for the disposition of HIV to bind to a CCR5 molecule. Plasmodium falciparum, one of the 
infectious organisms that causes malaria, has a disposition to spread through host red blood cells, a 
process that is reduced in dense, dehydrated red blood cells. In individuals with the sickle cell 
hemoglobin gene, red blood cells have a disposition to become dehydrated and thus increase in 
density. This disposition acts as a blocking disposition for the disposition of plasmodium to spread 
through red blood cells, a process requiring hydrated red blood cells. 
[16] shows how IDOSA annotations of genetic, phenotypic, and demographic data on Sa 
isolates maintained by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA)6 
can be used to infer a lattice or network of application ontologies for specific subfamilies of Sa-
related diseases, down to the level of specific strains. The method is generalizable to isolate 
repositories across the infectious disease domain. By leveraging the other extension ontologies 
within the IDO suite (Table 1), we can generate similar lattices for specific subfamilies of 
coronavirus-related diseases, influenza virus-related diseases, and so on. Together these would 
automatically form a larger network of infectious disease ontologies under IDO Core. This potential 
network of IDO ontologies can be used to define a strategy for constructing a taxonomy of 
infectious diseases incorporating both high-throughput genetic and molecular data, as well as clinical 
data. The IDO suite of ontologies can thereby help contribute to the advance of what is called 
‘personalized’ or ‘precision’ medicine, which depends upon effective classification and association of 
biological disease data with known clinical phenotypes and disease types.  
As we have seen, IDO Core aligns with OBO Foundry principles, imports a range of terms 
from widely used ontologies, covers a wide range of phenomena in the domain of infectious 
diseases, and has been used effectively to characterize an important resistance phenomenon in 
IDOSA. In the next section, we briefly highlight some of the other ontologies that purport to 
extend IDO Core.  
3 EXTENDING IDO Core 
An overview of each IDO extension ontology is included in Supplementary Data A, along with 
other disease ontologies employing IDO terms. The current state of each extension is provided in 
Table 1.  
 
Table 1  IDO Extension Ontologies: *=subject to re-engineering, **obsoleted and will be 
replaced; see Supplementary Data B for details 
Coronavirus Infectious Disease 
Ontology (CIDO)* [22, 23]  
 
Most recent version uploaded to Bioportal on 
May 4, 2020a  
 
6 http://www.narsa.net/ 
Influenza Ontology (FLU)* [24] Most recent version uploaded to BioPortal on 
August 20, 2015b  
Brucellosis Ontology (IDOBRU)* [7, 
25] 
Most recent version uploaded to BioPortal on March 
28, 2015c  
 IDO Virus (VIDO) [XX] Currently in development 
COVID-19 Infectious Disease 
Ontology [XX] 
Currently in development 
Dengue Ontology (IDODEN)* [26] Most recent version uploaded to BioPortal on 
February 17, 2014d  
Malaria Ontology (IDOMAL)** [27, 
28] 
Though obsoleted, IDOMAL is being hosted for 
legacy purposes.e  
Meningitis Ontology (IDOMEN)* 
[29]  
 
Draft version uploaded on November 27, 2019f  
Plant Disease Ontology (IDOPlant) 
[30] 
Draft version released in 2012g  
 
Staphylococcus aureus Infectious 
Disease Ontology (IDOSA) [6, 15, 16] 
Released on June 22, 2012h  
Schistosomiasis Ontology 
(IDOSCHISTO)* [31, 32] 
Most recent version uploaded on October 23, 2013i  
HIV Ontology (HIV)* [33, 34] Most recent version uploaded to BioPortal on April 
4, 2017j  
 ahttps://bioportal.bioontology.org/ontologies/CIDO, bhttps://bioportal.bioontology.org/ontologies/FLU, chttps:// 
bioportal.bioontology.org/ontologies/IDOBRU, dhttps://bioportal.bioontology.org/ontologies/IDODEN, ehttps:// 
github.com/VeuPathDB-ontology/IDOMAL, fhttps://github.com/cedricbere/IDOMEN, ghttp://purl.obolibrary.org/ 
obo/idoplant.owl, hhttps://github.com/awqbi/ido-staph, ihttps://github.com/gaoussoucamara/idoschisto, jhttps:// 
bioportal.bioontology.org/ontologies/HIV 
3.1 IDOBRU 
IDOBRU, the Brucellosis Infectious Disease Ontology, is maintained by the He research team at the 
University of Michigan, and is used to facilitate the integration and exchange of brucellosis 
information stored in widely used databases, including: 
• The Brucella Bioinformatics Portal (BBP) [35]: a portal for the search and analysis of 
individual Brucella genes; linked to more than 20 other databases and programs.  
• The Vaccine Investigation and Online Information Network7 (VIOLIN) a central repository 
for literature related to, and data resulting from, vaccine research that uses VO [19]. 
 
IDOBRU exhibits a well-organized hierarchy with BFO, OGMS, and IDO Core imported in full, 
and is a good exemplar of the IDO Core hub and spokes model, as can be seen in Table 2: 
 
 
7 http://www.violinet.org/ 
Table 2   
IDOBRU Axis Top Level IDOBRU Classes Imported OBO Ontology Class 
from which it descends 
host infection and 
zoonotic disease 
transmission 
process of establishing Brucella 
infection in host, 
brucellosis disposition, 
Brucella host role 
process of establishing an infection 
(IDO Core) 
zoonotic disposition (IDO Core) 
infectious agent host role (IDO Core) 
virulence factors and 
pathogenesis 
Brucella virulence factor, 
Brucella virulence factor 
disposition 
brucellosis pathogen role 
virulence factor (IDO Core), 
virulence factor disposition (IDO 
Core), 
pathogen role (IDO Core) 
symptoms brucellosis symptom symptom (OGMS) 
diagnosis brucellosis diagnosis diagnosis (OGMS) 
intentional release Brucella intentional release planned process (OBI)  
vaccine prevention brucellosis vaccine   vaccine (VO) 
treatment brucellosis treatment treatment (OGMS) 
 
In [7] IDOBRU classes are used to provide formalized representations of:  
• The mechanisms by which Brucella successfully establishes an infection in the host, including 
the crucial role played by Brucella virulence factors Brucella VirB1 protein and Brucella 
lipopolysaccharide (LPS) in the bacterium’s ability to survive and replicate within the 
vacuolar macrophage compartments of host cells  
• Brucellosis diagnoses using a PCR assay to test a Brucella gene omp-2 encoding for an outer 
membrane protein from patient’s blood sample 
• The intentional use of aerosolized Brucella as a weapon of bioterrorism, as well as the use of 
bleach for the purpose of disinfection in the case of a Brucella bioterrorist attack  
• WHO’s recommended standard treatment for uncomplicated brucellosis cases in adults and 
children that are 8 years of age or older (using Brucella vaccine terms imported from VO) 
He’s group has also used the ontology to provide a formal treatment of host-brucella interactions 
[25] and as the basis for an online IDOBRU SPARQL query interface.8  
3.2 IDOPlant  
IDOPlant [30] is a plant infectious disease ontology being developed under the auspices of the 
Planteome Project, which maintains a large database of annotations from plant genomic and 
phenomic studies [36]. IDOPlant forms part of the biotic plant stresses branch of the Planteome 
Plant Stress Ontology (PSO). It leverages IDO Core in axioms such as the following:  
• IDOPlant:process of establishing a Xanthomonas oryzae infection subclass-of IDOPlant:process of 
establishing a plant bacterial infection,  
• IDOPlant:process of establishing a plant bacterial infection subclass-of IDO:process of establishing an 
infection 
 
8 http://www.phidias.us/ bbp/idobru/sparql/index.php 
• IDOPlant:rice bacterial leaf blight disease subclass-of IDOPlant:plant bacterial disease 
• IDOPlant:plant bacterial disease subclass-of IDOPlant:plant infectious disease  
• IDOPlant:plant infectious disease subclass-of IDO:infectious disease 
 
3.3. IDOSCHISTO  
IDOSCHISTO is an extension of IDO Core focusing on schistosomiasis, a waterborne infectious 
disease caused by Schistosoma helminth parasites [31, 32]. It leverages IDO Core in axioms such as: 
• NCIBTaxon:Schistosoma subclass-of IDO:infectious agent 
IDOSCHISTO imports from NCBITaxon classes for a variety of snail species that serve as 
intermediary hosts for the disease, such as bulin and biomphalaria. The relation has_intermediary_host 
was created for IDOSCHISTO to link Schistosoma species to their intermediary hosts. Snail hosts are 
then linked to the class geographical_location, which has as subclasses the following defined classes: 
• intestinal schistosomiasis area  geographical location AND (adjacent_to SOME (location_of 
SOME bulinus)) 
• urinary schistosomiasis area  geographical location AND (adjacent_to SOME (location_of SOME 
biomphalaria)) 
Given the information encoded in the IDOSCHISTO concerning the role that the bulinus and 
biomphalaria species play in the transmission of schistosoma, these classes can be used in combination 
with IDOSCHISTO classes such as human distribution, snail distribution, and parasite distribution (which 
are subclasses of population distribution) to model risk factors for the spread of intestinal 
schistosomiasis and urinary schistosomiasis [32].  
IDOSCHISTO is designed to support epidemiological monitoring systems and has been 
used to annotate and query data from epidemiological investigations in Senegal. IDOSCHISTO 
maintains an instance hierarchy that contains terms for districts, as well as nearby water bodies, with 
adjacency relations asserted between them. The located_in relation is asserted between water bodies 
and the snail species that inhabit them, while schistosoma species are linked to snail species via the has_ 
intermediary _host relation. For example, Ndiaw is a district lying on the south bank of the Senegal 
River. Given the information encoded in IDOSCHISTO, a SPARQL query regarding which types 
of schistosomiasis the ndiaw population is exposed to will return the answers: intestinal_schistosomiasis and 
urinary_schistosomiasis [32]. 
4 IDO: NEW DEVELOPMENTS  
As with any ontology, IDO is always evolving. In this and the following section we detail some 
recent and future developments of the IDO suite.  
4.1 The importation of disease terms from the Human Disease Ontology (DOID) 
New disease terms were created for IDOMAL, IDOBRU, IDOMEN, IDODEN and IDOSA. But 
in line with OBO Foundry principles, they are being updated to import disease terms from DOID 
[37, 38]. FLU, IDOSCHISTO, and CIDO import, respectively, the terms DOID:influenza, DOID: 
schistosomiasis, and DOID:COVID-19. Like IDO, DOID incorporates the OGMS definition of 
disease. But while some DOID disease terms are defined partially in terms of underlying disorders 
(such as DOID:COVID-19), there is no consistency on this front. A better template is provided by 
IDOSA: Staphylococcus aureus infectious disease, defined as “Infectious disease that has a staphylococcus 
aureus infectious disorder as its material basis.” We will work with the DOID team to achieve 
consistency with the OGMS definition moving forward. 
4.2 Treatment of symptoms in IDO Core and its extensions 
Traditional disease classifications often place too much emphasis on similarities in symptoms, but 
the study of symptoms is of course still an important factor in any disease domain. Symptom was 
initially defined by OGMS disjunctively, thus as a defined class in BFO terms, that does not 
represent a single natural kind. More specifically, it was defined as either a quality of a patient that is 
observed by a patient or a process experienced by the patient, which in either case is hypothesized 
by the patient to be part of the realization of a disease [8]. The OGMS and IDO communities are 
working to refine the treatment of symptoms and the following definition is currently being 
considered: 
• OGMS:symptom =def. Process experienced by the patient, which can only be experienced by 
the patient, that is hypothesized to be clinically relevant. 
In line with this, all subclasses of symptom appearing within individual IDO extensions should be 
consistently classified as processes. (The treatment of symptoms in IDOPlant is a special case [30], 
since the OGMS definition requires a sentient host that can report its experiences. In IDOPlant, 
plant disease symptom is defined as “Feature of a plant that is of a type that can be hypothesized to be 
involved in the realization of a plant disease”.) 
 
4.3 Infectious Disease Epidemiology and Surveillance  
We have recently updated IDO Core to enhance its coverage of infectious disease 
epidemiology. IDO Core contains qualities of disease affected populations, such as infectious disease 
incidence rate, infectious disease mortality rate, and infectious disease endemicity, and we have recently added 
new terms for the corresponding sites at which these qualities are instantiated. For example: infectious 
disease endemic site, infectious disease free site, and infectious disease non-endemic site. Adding these classes 
allows them to serve as parent classes for the brucellosis specific classes brucellosis endemic site, 
brucellosis free site, and brucellosis non-endemic site currently used in IDOBRU. 
We have also introduced to IDO Core the terms holoendemicity, hypoendemicity, and 
mesoendemicity (previously from IDOMAL [28]) to represent the varying degrees to which diseases can 
be endemic within different populations. In several regions of sub-Saharan Africa, holoendemicity is 
frequently seen in malaria, in particular the strain caused by Plasmodium falciparum (with one study 
finding that traces of the pathogen were present in 98.6% of the population within a 4-month period 
[39]). Holoendemicity is also seen in ocular trachoma in certain areas of sub-Saharan Africa and in 
hepatitis B in areas of the Marquesas Islands. 
Drawing on the Vector Surveillance and Management Ontology (VSMO) [40], IDO Core 
has been expanded with terms for infectious disease surveillance. VSMO includes the following 
classes, all of which are subclasses of OBI:planned process: 
• surveillance process =def. Planned process with the objective to produce information about some 
evaluant with the purpose of, if justified by the information gathered, managing, directing, or 
protecting  
• pathogen surveillance =def. Surveillance process aiming to produce information about one or 
several objects, in the form of microorganisms, which have the role of pathogen  
• vector surveillance =def. Surveillance process aiming to produce information about one or several 
objects, in the form of arthropods, which have the role of serving as biological pathogen vectors 
Both pathogen surveillance and vector surveillance have been added IDO Core. The term surveillance process 
was not appropriate for inclusion in IDO, since it is not a term that has specifically to do with 
infectious disease. Its children in other ontologies might include, for example, intelligence surveillance, 
engineering surveillance, aircraft health surveillance, drug adverse event surveillance, and so forth. It will instead 
be moved up to OBI. Several IDO extension ontologies already contain coverage of infectious 
disease surveillance for the corresponding pathogen, and these ontologies will now be re-engineered 
as appropriate. FLU, in particular, has an extensive treatment of influenza surveillance as part of the 
Centers for Excellence in Influenza Research and Surveillance program [24]. The ontology is meant 
to be applicable to any virus sequence and surveillance collection project, consolidating sequence 
and surveillance terms from a variety of online databases. IDOSCHISTO contains a module 
devoted to the epidemiology of schistosomiasis. It contains classes such as prevention strategy and 
control strategy, each of which has a variety of sub-classes pertaining to the prevention and control of 
schistosomiasis. 
The following is an example of a hierarchy of surveillance related terms, all of which (below 
OBI:planned process) were created for IDOBRU: 
OBI:planned process 
Public health Surveillance (up to OBI) 
           biosurveillance  
                 infectious disease surveillance 
  human infectious disease surveillance  
human brucellosis surveillance 
                 veterinary infectious disease surveillance  
swine brucellosis surveillance 
cat brucellosis surveillance 
goat brucellosis surveillance 
camel brucellosis surveillance 
horse brucellosis surveillance 
sheep brucellosis surveillance  
 
Public health surveillance and biosurveillance will be ported to an external ontology such as OBI. Infectious 
disease surveillance will be promoted to IDO Core and then imported from there to IDOBRU.  
IDO Core’s expanded coverage of epidemiology will be developed through collaboration 
with the developers of the epidemiology focused ontologies Apollo Structured Vocabulary (Apollo-
SV) [41] or Genomic Epidemiology Ontology (GenEpio) [42]. GenEpio itself reuses a number of 
important IDO Core terms and IDO extensions will for its part incorporate appropriate terms from 
Apollo-SV and GenEpio. As in all biomedical ontology, each of the mentioned ontologies evolves in 
response to term requests from users in order to accommodate the community’s needs.  
Apollo-SV provides a standardized vocabulary for terms and relations required for the 
interoperation between epidemic simulator models and public health application software that 
interface with these models. Apollo-SV, which draws heavily on the Information Artifact Ontology 
(IOA) [43], provides a variety of pertinent terms including: 
• Terms pertaining to disease control, including: infectious disease control strategy (a child of 
IAO:plan specification), which has subclasses such as vector control strategy, place closure control 
strategy, travel-related infectious disease control strategy, and quarantine control strategy, the first three of 
which have more specific subclasses of their own; processes such as infectious disease control 
strategy execution 
• Terms pertaining to disease surveillance, including: disease surveillance objective specification; 
subclasses of IAO:algorithm such as disease transmission model and epidemic model; simulation software 
(a child of IAO:software) and its subclasses, including disease transmission model software, infectious 
disease forecasting software, and pathogen evolution model; subclasses of OBI:planned process such as 
disease surveillance, infectious disease forecast, and epidemic simulating 
• Terms relating to the spread of disease, including: processes such as infection in ecosystem and its 
subclasses endemic, epidemic and infection in population 
4.4 Partitioning of the IDO suite  
While currently existing IDO extensions were designed as direct extensions of the IDO Core, in the 
future we will be taking advantage of the fact that IDO extensions can be partitioned into subgroups 
on the basis of pathogen-type. Under this partitioning, the following reference ontologies will serve 
as direct extensions of IDO Core: IDO-Bacteria, IDO-Virus, IDO-Fungus and IDO-Parasite. 
IDOSA, IDOMEN, IDOTUB and IDOBRU would then be reengineered as extensions of IDO-
Bacteria. FLU, HIV, IDODEN and CIDO would extend from IDO-Virus, while IDOSCHISTO 
and a new ontology for malaria (replacing IDOMAL) will extend from IDO-Parasite: 
 
Figure 2 
We will also define IDO extension ontologies for vector-borne diseases on the basis of an extension 
of IDO Core – IDO VectorBorne – consisting of just those terms needed to deal with vector-borne 
diseases in a pathogen neutral fashion. Extension ontologies for specific vector-borne diseases 
would then be developed as extensions from IDO-VectorBorne [16].  
5 The Coronavirus Infectious Disease Ontology (CIDO) and IDO Virus (VIDO) 
The Coronavirus Infectious Disease Ontology (CIDO) deals with coronavirus infectious 
diseases in general. CIDO imports terms from a wide range of ontologies, including IDO Core 
ChEBI, the National Drug File - Reference Terminology (NDF-RT), UBERON, GO, VO, and the 
NCBITaxon. In addition, CIDO introduces 8 terms specific to the coronavirus domain. Alignment 
with IDO Core, however, will require much curation (see Supplementary Data B for details).  
One application of CIDO is to the analysis and integration of information on anti-
coronavirus drugs to facilitate drug repurposing against COVID-19. In a recent study [22], members 
of the CIDO team used text mining to identify chemical drugs and antibodies effective against at 
least one human coronavirus infection in vitro or in vivo and then mapped these drugs to ChEBI, the 
Drug Ontology (DrugOn) [44], and NDF-RT, each of which provide logical axioms linking drugs to 
their roles and mechanisms of action. This information was then extracted for analysis. Further 
relations will be built into CIDO linking drugs, coronaviruses, and the conditions under which the 
drugs work against the coronaviruses. CIDO is also being used in ongoing work to represent 
vaccines against coronavirus. In [23] reverse vaccinology and machine learning is used to predict 
potential vaccine targets for safe and effective COVID-19 vaccine development. The CIDO team 
will systematically annotate these vaccine candidates, along with their formulations and host 
responses, while working with the VO team to ontologically model and analyze these vaccines. To 
facilitate vaccine design, CIDO will be used in a further study to investigate host-pathogen 
interactions in order to better understand protective immune mechanisms.  
IDO Virus is in the later stages of its development under John Beverley and collaborators as 
a preparation for the re-architecting of CIDO as the extension of IDO Virus for coronavirus 
diseases. IDO Virus will then facilitate the construction of ontology modules focused exclusively on 
SARS-coronavirus, which caused the 2002-2003 SARS outbreak, and SARS-CoV-2, which is causing 
the current coronavirus (COVID-19) pandemic. Our immediate priority is to fast track the creation 
of an ontology concerning COVID-19 - IDO-COVID-19 - as an extension of CIDO. (The Protein 
Ontology consortium has recently created new terms dealing with SARS-CoV-2 proteins.)9  
Recall that each IDO extension ontology should be developed in a modular fashion, 
providing terms specific to their own domains which build upon the disease and pathogen-neutral 
terms imported from IDO Core. In the typical case, terms from extension ontologies are created via 
downward population of the upper level terms provided by IDO Core. For example: 
• IDOSA:Staphylococcus aureus infectious disease subclass-of IDO:infectious disease 
 
Higher-level terms needed within a particular extension ontology will be added to IDO Core where 
the term is specific to the infectious disease domain and is truly pathogen neutral. If the relevant 
term is included in an OBO Foundry ontology then it can be imported from there.  
To create IDO Virus, relevant IDO Core terms were introduced by adding the term ‘virus’ to 
generate child terms pertaining to viral disease. Thus, to give a few examples, IDO Virus extends 
IDO Core by introducing terms such as: 
• virus disorder =def. Infectious disorder that exists as a result of processes initiated by members 
of a virus population.  
• viral disease =def. Infectious disease whose physical basis is a virus disorder that is clinically 
abnormal in virtue of the presence of the relevant virus population 
• viral disease course =def. Infectious disease course that realizes a viral disease  
 
9 Found here https://proconsortium.org/download/development/pro_sars2.obo; and here: https:// 
proconsortium.org/download/ development/pro_sars2.gpi. 
 
paralleling the IDO Core extension of OGMS introduced earlier. For example, IDO Core:subclinical 
infection – an infection that is part of an asymptomatic host - provides resources needed to represent 
asymptomatic viral infections: 
• subclinical virus infection =def. Subclinical infection for which the infectious agent population is 
a virus population  
 
As viral infections need not result in the manifestation of symptoms, yet nevertheless satisfy all other 
criteria for inclusion as infections.  
Leveraging IDO Virus, relevant terms will be added to CIDO and IDO-COVID-19. Figure 3 
provides a summary of several important links:  
 
  
Figure 3 
 
Representing asymptomatic infection is of crucial importance, as the spread of SARS-CoV-2 makes 
clear. IDO Virus provides CIDO and IDO-COVID-19 needed resources in that respect: 
• CIDO:subclinical coronavirus infection subclass-of VIDO:subclinical virus infection 
• IDO-COVID-19:subclinical SARS-CoV-2 infection subclass-of CIDO:subclinical coronavirus 
infection 
 
While distinguishing these instances from symptomatic cases:  
• CIDO:coronavirus disorder subclass-of VIDO:virus disorder 
• IDO-COVID-19:SARS-CoV-2 disorder subclass-of CIDO:coronavirus disorder  
 
These disorders are, moreover, the material bases for relevant diseases and disease courses, 
themselves illustrating links among IDO Virus, CIDO, and IDO-COVID-19: 
• CIDO:coronavirus disease subclass-of VIDO:viral disease 
• IDO-COVID-19:COVID-19 subclass-of CIDO:coronavirus disease  
• CIDO:coronavirus disease course subclass-of VIDO:viral disease course 
• IDO-COVID-19:COVID-19 disease course subclass-of CIDO:coronavirus disease course  
 
Where the relevant disease courses have the expected participants:  
• CIDO:coronavirus disease course has participant CIDO:coronavirus 
• IDO-COVID-19:COVID-19 disease course has participant IDO-COVID-19:SARS-CoV-2 
 
Viral disease courses involve process parts which are useful for characterizing the development of a 
given virus in a host. This in mind, IDO Virus imports terms from GO [2] to reflect such processes: 
• VIDO:viral disease course has part GO:virus replication process  
• VIDO:viral disease course has part GO:virus synthesis process 
 
Allowing the following connections to CIDO:  
• CIDO:coronavirus disease course has part CIDO:coronavirus synthesis process 
• CIDO:coronavirus synthesis process subclass-of GO:virus synthesis process 
• CIDO:coronavirus disease course has part CIDO:coronavirus replication process 
• CIDO:coronavirus replication process subclass-of GO:virus replication process 
 
And then IDO-COVID-19: 
• IDO-COVID-19:SARS-CoV-2 subclass-of CIDO:coronavirus 
• IDO-COVID-19:COVID-19 disease course has part IDO-COVID-19:COVID-19 synthesis 
process 
• IDO-COVID-19:SARS-CoV-2 synthesis process subclass-of CIDO:coronavirus synthesis process 
• IDO-COVID-19:COVID-19 disease course has part IDO-COVID-19: SARS-CoV-2 replication 
process 
• IDO-COVID-19:SARS-CoV-2 replication process subclass-of CIDO:coronavirus replication process 
 
The introduction in IDO Virus of the many stages of viral reproduction will assist researchers in 
classifying specific mechanisms of efficacy for given antivirals.  
To see how, consider IDO Core includes a class populated by antiviral instances, and this 
class is extended in IDO Virus: 
• viricidal disposition =def. Antiviral disposition to kill viruses 
• viricidal =def. Antiviral bearing the viricidal disposition 
• virostatic disposition =def. Antiviral disposition to inhibit the lifecycle of viruses  
• virostatic =def. Antiviral bearing the virostatic disposition  
 
Logical definitions can also be constructed for these terms, such as:  
• viricidal  antiviral AND has_disposition SOME viricidal disposition 
• viricidal disposition  antiviral disposition AND inheres_in SOME (antiviral) AND realized_in 
ONLY (process AND results_in SOME (virus death temporal boundary)) 
• virostatic  antiviral AND has_disposition SOME virostatic disposition 
• virostatic disposition  antiviral disposition AND inheres_in SOME (antiviral) AND realized_in 
ONLY (process AND negatively_regulates SOME viral reproduction)) 
 
By introducing terms such as:  
• virus death temporal boundary =def. Organism death temporal boundary that marks the end of 
the life cycle of a virus 
• virus birth temporal boundary =def. Organism birth temporal boundary that marks the beginning 
of the life of a virus 
• virus reproduction =def. Reproduction process involving the production of a virus containing 
some portion of genetic material inherited from a parent virus 
 
Themselves relying on IDO Core terms such as IDO:organism death temporal boundary, IDO:organism 
birth temporal boundary, and GO:reproduction, the latter defined as the production of individuals 
containing some portion of genetic material inherited from one or more parent organisms. These 
terms allow for characterization of negative regulation of viruses via drugs targeting specific parts of 
the virus reproduction process in these ontologies, for example in CIDO:  
• CIDO:negative regulation of coronavirus replication subclass-of IDO Virus:negative regulation of virus 
replication 
• CIDO:negative regulation of coronavirus replication negatively regulates SOME CIDO:coronavirus 
replication process 
• CIDO:negative regulation of coronavirus synthesis negatively regulates SOME CIDO:coronavirus 
synthesis process 
 
And in the case of IDO-COVID-19:  
• IDO-COVID-19:negative regulation of SARS-CoV-2 replication subclass-of CIDO:negative 
regulation of coronavirus replication 
• IDO-COVID-19:negative regulation of SARS-CoV-2 synthesis subclass-of CIDO:negative regulation 
of coronavirus synthesis 
• IDO-COVID-19:negative regulation of coronavirus synthesis negatively regulates SOME IDO-
COVID-19: SARS-CoV-2 synthesis process 
 
Such classes provide resources needed to annotate and unify existing data concerning coronavirus 
antivirals in general, and COVID-19 antivirals in particular. Given the pressing need for progress in 
combatting the spread of these viruses in humans, consolidating and interpreting such data is of 
paramount importance. As is having terms needed for viral disease monitoring, such as the 
following terms in IDO Virus extending IDO:infectious disease epidemic and IDO:infectious disease 
pandemic, respectively:  
• viral disease epidemic =def. Infectious disease epidemic largely involving viruses 
• viral disease pandemic =def. Infectious disease pandemic consisting of viral disease epidemics 
 
Themselves easily extended to CIDO:  
• coronavirus epidemic =def. Viral disease epidemic largely involving members of the species 
Coronaviridae. 
• coronavirus pandemic =def. Viral disease pandemic consisting of coronavirus epidemics 
 
And from CIDO to IDO-COVID-19: 
• COVID-19 epidemic =def. Coronavirus epidemic largely involving members of the virus strain 
SARS-CoV-2 
• COVID-19 pandemic =def. Coronavirus pandemic consisting of COVID-19 epidemics 
 
Refining and expanding these terms in IDO Virus, CIDO, and IDO-COVID-19 is still in progress, 
but made much easier by importing IDO Core as a starting point.  
A similar strategy to that illustrated above will be used to link IDO Virus to existing virus 
ontologies, for example: 
• FLU:influenza A virus infection is a subclass of VIDO:virus infection 
• HIV:HIV virus infection is a subclass of VIDO:virus infection 
 
Additionally, as should be clear, IDO Virus provides terms needed to distinguish bacterial, fungal, 
and viral infectious agents, infectious agent dispositions realized in relevant infectious processes. 
This makes possible deploying the preceding strategy to the construction of IDO-Bacteria, IDO-
Fungus, and IDO-Parasite, and the linking of these reference ontologies to IDO Core. We can then 
use these reference ontologies to distinguish between viral, bacterial, fungal, and parasitic infections, 
between viral, bacterial, fungal, and parasitic infectious diseases, and so on, linking existing 
ontologies covering more specific bacteria, fungi, and parasites to IDO Core. 
 Other ontology initiatives being developed to support curation of COVID-19 data outside 
the IDO framework include:  
• The WHO COVID-19 Rapid Version CRF, which provides a semantic data model for the 
RAPID version (23 March 2020) of the WHO’s COVID-19 case record form10  
• The COVID-19 Surveillance Ontology supports COVID-19 surveillance in primary care by 
facilitating the monitoring of COVID-19 cases and related respiratory conditions using data 
from multiple brands of computerized medical record systems11  
• The Linked COVID-19 Data Ontology uses RDF to present COVID-19 datasets from the 
European Centre for Disease Prevention and Control, John Hopkins University and the 
Robert Koch-Institut.12 (At present this is little more than a list of datasets rather than a 
bona fide ontology.) 
 
10 https:// bioportal.bioontology.org/ontologies/COVIDCRFRAPID   
11 https:// bioportal.bioontology.org/ontologies/COVID19  
12 https://github.com/Research-Squirrel-Engineers/COVID-19 
• The NASA Jet Propulsion Laboratory’s COVID-19 Research Knowledge Graph builds a 
knowledge graph from the COVID-19 Open Research Dataset (CORD-19)13  
 
These are all stand-alone initiatives, and are thus subject to the silo problems documented in the 
foregoing.  
 
6. IDO Applications 
 
Ontology metadata can be used to combine heterogeneous bodies of research data to enable 
structured querying and analysis [45]. [46] applies these same methods to immunology data using 
IDO related ontologies such as OBI [13] and VO [19]. The following is an incomplete list of 
databases to which IDO ontology annotations are applied:  
• The Eukaryotic Pathogen Genomics Database14; genomic and other data for eukaryotic 
pathogens including Cryptosporidium, Giardia, Plasmodium, Theileria, Toxoplasma, and Trichomonas 
strains.  
• VectorBase: Bioinformatics Resource for Invertebrate Vectors of Human Pathogens15; 
genomic and other data for a variety of invertabrae vectors of human pathogens; until 
recently, several terms from IDOMAL [27, 47], as well as terms from the Mosquito 
Insecticide Resistance Ontology (MIRO) [48], were used in the annotation of its datasets. 
Both of these ontologies have since been obsoleted. A team of researchers at the University 
of Pennsylvania led by Chris Stoeckert is in the process of replacing the obsoleted IDOMAL 
and MIRO terms used in VectorBase with suitable terms from OBO Foundry Ontologies. 
• Recently the National Institute of Allergy and Infectious Diseases awarded a new 5-year 
contract, worth up to $7.2 million in 2019-2020, to support the integration of the EUPATH 
database and VectorBase.16 The Stoeckert team has since joined these resources into one 
bioinformatics resource, the Eukaryotic Pathogen, Host & Vector Genomics Resource 
(VEuPathDB). The project involves the leveraging of ontologies to expand the 
harmonization of semantic terms across all sites. Understanding of what the data stored in 
VEuPathDB is about is encoded through the use of the VEuPathDB application ontology 
[49]. IDO Core will play a role in this project, as the VEuPathDB ontology imports IDO 
Core terms such as: human pathogenicity disposition, infection, infection prevalence, pathogen role, and 
primary infection, each of which are used in the annotation of its datasets. 
• Influenza Research Database17 [50]; makes use of IDO Core and FLU. 
• Virus Pathogen Resource18  
• Pathogen-Host Interaction Data Integration and Analysis System [51],  
• Victors virulence factors database [51] 
 
In addition to providing a basis for database interoperability, IDO annotations can also serve a 
variety of other purposes, including [5]:  
 
13 https://github.com/nasa-jpl-cord-19/covid19-knowledge-graph 
14 https://eupathdb.org/eupathdb/ 
15 http://vectorbase.org 
16 https://eurekalert.org/pub_releases/2019-10/uop-nat101519.php  
17 http://www.fludb.org 
18 http://www.viprbrc.org 
• Enhanced interpretation of data from genome-wide and high-throughput experiments. 
• Use in software tools for the analysis and interpretation of microarray data, and in the 
development of new bioinformatic approaches to analysis of such data. 
• The integration of text-mining approaches with microarray data to facilitate disease gene 
identification.  
 
Reflecting their use in supporting knowledge re-use and automated reasoning, ontologies have been 
implemented in a variety of applications for the enhancement of patient diagnosis, care management 
and clinical decision support [52-56]. A brief overview and further references are provided in [57]. In 
the fields of infectious disease Clinical Decision Support Systems (CDSSs) are commonly used in 
diagnostic assistance, guidance in the prescription of anti-infectives, biosurveillance, and vector 
control. The use of ontologies in CDSSs is increasingly on the rise: 
 
• Use of antibiotic decision support systems (ADSSs) has been shown to be effective in mitigating 
inappropriate antibiotic prescribing and lowering local antimicrobial resistance [58-60]. To 
facilitate interoperability and widespread circulation of future ADSSs, a Bacterial Clinical 
Infectious Disease Ontology (BCIDO) has been developed from IDO Core [61]. 
• IDDAP, a recently developed ontology-driven clinical decision support system for infectious 
disease diagnosis and antibiotic prescription makes heavy use of IDO Core [62].    
• The Dengue Decision Support System (DDSS) is an ontology driven computational application 
developed at Colorado State University [63, 64] with the aim of guiding the implementation of 
locally appropriate Dengue and Dengue Vector control programs. The DDSS is used in 
conjunction with Chaak, a cell phone-based system for i) the field capture of data relating to 
Dengue vector surveillance; and ii) the rapid transfer of the data to the central DDSS database 
[65]. The DDSS makes use of IDOMAL [27], as well as the related ontologies MIRO [48] and 
VSMO [40]. Given its use of obsoleted ontologies the DDSS requires reengineering.  
 
7 CONCLUDING REMARKS 
Successful information-driven research on COVID-19 needs to be able to integrate the 
already massive and exponentially growing body of research and data concerning coronavirus 
diseases. Ontologies such as IDO Virus, CIDO and IDO-COVID-19 fill this need by providing a 
standardized, computer-interpretable representation of heterogenous coronavirus knowledge. 
Another potential application of this work is to ontology-based deep learning, for instance as 
illustrated in [66], which describes a novel method for learning features of entities such as proteins 
and viruses from their associations to ontology classes, and describes how this method can be 
employed for fast identification of virus–host interactions that can shed light on potential treatments 
and drug discoveries. Because these ontologies are built as part of an interoperable suite of IDO 
ontology modules, it becomes easier, for example, to compare COVID-19 to other respiratory 
diseases such as SARS, MERS, and influenza – along multiple dimensions including underlying 
disorders, pathogen features (such as strain, virulence factors, and drug resistance), host-pathogen 
interactions, routes of transmission, anatomical sites of infection, genetic and environmental 
variables, symptoms, diagnostic criteria, disease courses, prevention measures and so on.  
The utility of the IDO framework turns not least on the fact that we will continue to face the 
threat of novel viruses (as well as bacteria and parasites) in the future, and the IDO suite provides an 
easy to follow recipe for building new pathogen-specific ontologies in a way that allows easy 
comparison, along multiple dimensions, of novel pathogens and diseases with pathogens and 
diseases about which data have already been assembled.  
The IDO strategy also brings about a situation in which there is a community trained in how 
to build, use, understand and correct both single ontologies and groups of ontologies that fit 
together. This promotes coordination of data curation as it relates to data crossing disciplinary 
boundaries, for example between vaccine research and pathogen genomics. Moreover, the IDO 
corpus provides a set of rigorously curated definitions of terms used in infectious disease research 
that can be employed to provide a useful vehicle for cross-disciplinary collaboration, allowing 
specialists in one sub-domain to rapidly gain an understanding of the meanings of the technical 
terms used in neighboring domains. 
Finally, the IDO ontologies can contribution to addressing a further urgent problem faced 
not merely by COVID-19 research but by contemporary biomedical research in general. This is the 
problem of reproducibility. This problem applies not only to scientific findings which are the results of 
experimental studies, but also to findings deriving from the application of different types of 
diagnostic tests. For an experiment, or a test, to be reproducible, it is crucial that we have a clear 
understanding of how the experimental or test results were obtained. For this to be possible, 
however, it is crucial that the constituent processes are described in a terminology that is widely used 
and whose terms are well defined. We believe that, when used in combination with the Ontology for 
Biomedical Investigations (OBI) [13], IDO offers a strategy to obtain comparable and integratable 
provenance metadata for the data generated in infectious disease research.  
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Supplementary Data A 
Table 1  Ontologies building on the OGMS treatment of disease and diagnosis 
Agronomy Ontology (Agro) [67] Apollo Structured Vocabulary (Apollo-SV) [41] 
Beta Cell Genomics Ontology (BCGO) [68] Cardiovascular Disease Ontology (CVDO) [69] 
Coronavirus Infectious Disease Ontology (CIDO) [22, 
23] 
Human Disease Ontology (DOID) [37, 38] 
Drug Ontology (DrugON) [41] VEuPathDB ontology (EUPATH) [49] 
Influenza Ontology (FLU) [24] Genomic Epidemiology Ontology (GenEpio) [42] 
Hypertension Ontology (HTN) Infectious Disease Ontology (IDO) [5] 
Brucellosis Ontology (IDOBRU) [7, 25] Meningitis Ontology (IDOMEN) [29] 
The Plant Disease Ontology (IDOPlant) [30] Staph aureus Infectious Disease Ontology (IDOSA) [6, 
15, 16]    
Schistosomiasis Ontology (IDOSCHISTO) [31, 32] 
 
Mental Functioning Ontology (MFO) [70] 
Mental Diseases Ontology (MFOMD) [71] Monarch Disease Ontology (MonDO) [72] 
Neurological Disease Ontology (ND) [73] Ontology of Adverse Events (OAE) [74] 
Ontology for Biomedical Investigations (OBI) [13] OBI-NIAID-GSC-BRC-view 
Ontology for Biobanking (OBIB) [75] Ocular Disease Ontology (ODO) [76] 
Oral Health and Disease Ontology (OHD) [77] Ontology of Host Pathogen Interactions (OHPI) [51] 
Ontology of Laboratory Animal Medicine (OLAM) Ontologized MIABIS (OMIABIS) [78] 
Ontology of Medically Relevant Social Entities 
(OMRSE) [79] 
Obstetric and Neonatal Ontology (ONTONEO) [80] 
 
Ontology of Precision Medicine and Investigation 
(OPMI) 
Prescription of Drugs Ontology (PDRO) [81] 
Planarian Phenotype Ontology (PLANP) Vaccine Ontology (VO) [19] 
Vital Sign Ontology (VSO) [82]  
 
Table 2  Overview of IDO extension ontologies that have been developed or planned.  
Malaria Ontology 
(IDOMAL) [27, 
28] 
 
Created by the Christos Louis team at the Institute of Molecular Biology and 
Biochemistry (IMBB) in Crete, Greece, IDOMAL covers both clinical and 
epidemiological aspects of malaria, disease and vector biology, as well as 
intervention attempts to control the disease. IDOMAL was originally 
developed in the context of VectorBase (http://vectorbase.org). 
Dengue Ontology 
(IDODEN) [26] 
 
Also developed by the Louis research team at IMBB, IDODEN covers all 
aspects of dengue fever including disease biology, epidemiology, clinical 
features, and vector entomology. IDODEN was developed in the context of 
VectorBase and its structure was designed to mirror that of IDOMAL. 
Intended for use in Dengue decision support systems.  
Brucellosis 
Ontology 
(IDOBRU) [7, 25] 
Developed by Yongqun He and his team at the University of Michigan, 
IDOBRU focuses on Brucellosis, a highly contagious zoonotic infectious 
disease caused by the intracellular, Gram-negative bacteria Brucella. IDOBRU 
encompasses the domains of clinical care, public health, and biomedical 
research, along seven major axes: host infection and zoonotic disease 
transmission, symptoms, virulence factors and pathogenesis, diagnosis, 
intentional release, vaccine prevention, and treatment.  
Influenza 
Ontology  
(FLU) [24] 
 
Developed by Richard Scheuermann, Lynn Schriml, Joane Luciano, and 
Burke Squires, FLU covers the natural, experimental and clinical realms 
related to influenza virus life cycle, infection and disease. FLU utilizes OBI 
classes for components of materials, qualities, and processes to map 
influenza virus sequence and surveillance terms to their corresponding 
materials and qualities. FLU is applied to data collected by the Centers for 
Excellence in Influenza Research and Surveillance (CEIRS) project to help 
researchers more easily elucidate influenza virulence and pathogenesis 
etiology. 
Staphylococcus aureus 
Infectious Disease 
Ontology 
(IDOSA) [6, 15, 
16] 
Developed by Lindsay Cowell, Barry Smith and Albert Goldfain, in 
collaboration with Dr. Vance Fowler at Duke University Medical Center, 
IDOSA focuses on Staph aureus (Sa) infection diseases. The ontology is 
used to analyze networks of functionally related gene products to identify 
host genes conferring susceptibility to Staphylococcus aureus bacteremia and 
has the potential to provide a classification of Sa that allows automated 
inference of resistance profiles. 
HIV Ontology 
(HIV) 
 
Developed by Martin Schiller of UNLV, the HIV ontology is intended to 
cover all types of HIV data and information; intended for use in the 
HIVToolbox web application [35, 36].  
Schistosomiasis 
Ontology 
(IDOSCHISTO) 
[31, 32] 
 
Developed by team of researchers based in Senegal led by Dr. Gaoussou 
Camara, IDOSCHISTO focuses on schistosomiasis, a waterborne infectious 
disease caused by Schistosoma helminth parasites. The ontology is organized 
into 3 main sub-modules; i) Biology, e.g. pathogen/host interactions, host 
physiological reactions to the disease, pathogen taxonomy and life-cycle; ii) 
Epidemiology, for example risk factors, spread of disease, means to prevent 
and control; and iii) Clinical, including symptoms that influence differential 
diagnoses and treatment decisions. 
Plant Disease 
Ontology 
(IDOPlant) [30] 
Under active development within the context of the Planteome Project, 
IDOPlant provides a comprehensive reference ontology for any infectious 
plant disease. The main aims of IDOPlant are to “provide plant scientists 
 with the means identify genomic and genetic signatures host-pathogen 
interactions, resistance, or susceptibility, and to help agronomists and 
farmers by developing tools to identify disease phenotypes and gather 
epidemiological statistics” [30]. 
Meningitis 
Ontology 
(IDOMEN) [29]  
 
Also developed by Dr. Camara’s team, IDOMEN focuses on meningitis, a 
disease caused by the gram-negative bacteria, Neisseria meningitidis. IDOMEN 
covers the meningitis domain along three main axes: i) biological (immunity, 
virulence factors, pathogen and host biology); ii) clinical (clinical 
manifestations, laboratory tests and findings, diagnosis and treatment); iii) 
epidemiological (surveillance, prevention, epidemic emergence factors such 
as risk behaviors, climate and environment). IDOMEN is designed to assist 
in the analysis and filtering of data collected on social media platforms such 
as Twitter to help improve the early detection of meningitis epidemic risks in 
sub-Saharan Africa. Increasingly, search queries, social media posts, and web 
server access logs have been employed for disease surveillance. Digital 
platforms provide real time data streams from which information related to 
public health can be extracted in a timely manner at low to virtually no cost. 
By mining these data sources for traces of health-related activities, they can 
be transformed into useful metrics for inclusion in statistical estimation 
models for disease incidence. Google, Wikipedia and Twitter have each been 
investigated as tools for quantifying disease incidence rates [83-85]. 
Ontology-based approaches to internet-based disease surveillance have also 
been developed and applied with good success [86, 87]    
Coronavirus  
Infectious Disease  
Ontology (CIDO) 
[22, 23] 
Initiated by Yongqun He and Hong Yu, CIDO was developed by a 
collaborative group of researchers in both the US and in China in response 
to the recent COVID-19 outbreaks. CIDO provides a standardized human- 
and computer-interpretable annotation and representation of various 
coronavirus infectious diseases including their etiology, transmission, 
epidemiology, pathogenesis, diagnosis, prevention and treatment. 
IDO Tuberculosis 
(IDOTUB) 
Planned, but is not yet currently in development. 
IDO Infective 
Endocarditis 
Planned, but not yet currently in development. Preliminary work is available 
online: https://sivsmusings. wordpress.com/ 
 
Table 3  Some other ontologies within the infectious disease domain that make use of IDO Core. 
Vaccine 
Ontology (VO) 
[19] 
Developed in collaboration with the IDO Core team, VO has strong ties to 
the IDO initiative. Maintained by the He team at the University of Michigan, 
VO focuses on the classification of vaccines and vaccine components, 
vaccine quality and phenotypes, and host immune response to vaccines. VO 
is used in the Vaccine Investigation and Online Information Network 
(VIOLIN, http://www.violinet.org/) a central repository for literature related 
to, and data resulting from, vaccine research. 
Bacterial Clinical  
Infectious 
Disease  
Ontology 
(BCIDO) [61] 
BCIDO provides a controlled terminology for clinical bacterial infectious 
diseases along with domain knowledge commonly used in the hospital in-
patient setting. BCIDO was designed to augment the use of ADSSs, thus 
serving as a tool to guide differential bacterial diagnoses and to assist in the 
prescribing of appropriate antimicrobial treatments. As such, BCIDO 
“encompasses terms and knowledge about common clinical presentations of 
[bacterial] infections, patient specific factors that influence differential 
diagnoses and treatment options, the [bacteria] themselves, and the 
antimicrobial agents used to treat infections” [61]. Though not an IDO 
extension per se, BCIDO imports IDO Core in full. 
Vector 
Surveillance and 
Management 
Ontology 
(VSMO) [40]  
 
Developed by a team of researchers at Colorado State University led by Drs. 
Lars Eisen and Saul Lozano, in collaboration with Dr. Cowell, VSMO covers 
the domain of surveillance and management of vectors and vector-borne 
pathogens, with special emphasis on content to support operational activities 
through inclusion in databases, data management systems and decision 
support systems [40]. The ontology includes terms for i) arthropod species 
capable of being biological vectors and for pathogen species transmitted by 
arthropod vectors; ii) chemical compounds relevant to insecticide resistance 
and chemical pesticide active substances (originating from MIRO); iii) terms 
for equipment used to collect or control vectors or vertebrae pathogen hosts, 
and tools used to kill vectors or prevent contact with humans. In consultation 
with the IDO Core developers, the relation has_vector was created for VSMO 
to link pathogens to their biological vectors.  
Genomic 
Epidemiology 
Ontology  
(GenEpio) [42]  
  
GenEpio is a controlled vocabulary for infectious disease surveillance and 
outbreak investigations implementing whole genome sequencing (WGS) of 
microbial pathogens. GenEpio aims to enable the integration and promotion 
of all contextual information required to interpret pathogen genomics data, 
including critical knowledge about sequencing pipelines and sequence quality; 
lab results describing antimicrobial resistance and virulence phenotypes; 
epidemiological data concerning potential sources of risk and exposure; as 
well as data about susceptible populations and geographical distributions of 
pathogen strain [42]. GenEpio is currently being integrated into IRIDA 
(Integrated Rapid Infectious Disease Analysis), a user-friendly, decentralized, 
open-source bioinformatics and analytical web platform to support real-time 
infectious disease outbreak investigations using WGS data [88].  
 
 
